129 related articles for article (PubMed ID: 3134309)
1. Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Pereyra-Alfonso S; Haedo A; Bal de Kier Joffé E
Int J Cancer; 1988 Jul; 42(1):59-63. PubMed ID: 3134309
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Pereyra-Alfonso S; Solarz GR; Bal de Kier Joffé E
Clin Exp Metastasis; 1992 Nov; 10(6):395-401. PubMed ID: 1451349
[TBL] [Abstract][Full Text] [Related]
3. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.
Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV
Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597
[TBL] [Abstract][Full Text] [Related]
4. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas.
Alonso DF; Farías EF; Bal de Kier Joffé E
Cancer Lett; 1993 Jul; 70(3):181-7. PubMed ID: 8353814
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
[TBL] [Abstract][Full Text] [Related]
6. Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth.
Aguirre Ghiso J; Diament M; D'elia I; Bal de Kier Joffé E; Klein S
Tumour Biol; 1997; 18(1):41-52. PubMed ID: 8989924
[TBL] [Abstract][Full Text] [Related]
7. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
8. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
Yu HR; Schultz RM
Cancer Res; 1990 Dec; 50(23):7623-33. PubMed ID: 1701350
[TBL] [Abstract][Full Text] [Related]
9. Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.
Bal de Kier Joffé E; Alonso DF; Puricelli L
Clin Exp Metastasis; 1991; 9(1):51-6. PubMed ID: 2015717
[TBL] [Abstract][Full Text] [Related]
10. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
[TBL] [Abstract][Full Text] [Related]
11. Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Korczak B; Kerbel RS; Dennis J
Int J Cancer; 1991 Jun; 48(4):557-61. PubMed ID: 2045200
[TBL] [Abstract][Full Text] [Related]
12. Relationship between circulating plasminogen activators and tumor development in mice.
Colombi M; Rebessi L; Boiocchi M; Barlati S
Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
[TBL] [Abstract][Full Text] [Related]
13. Production of protease inhibitors by postsurgical macrophages.
Fukasawa M; Campeau JD; Girgis W; Bryant SM; Rodgers KE; DiZerega GS
J Surg Res; 1989 Mar; 46(3):256-61. PubMed ID: 2493532
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R
Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056
[TBL] [Abstract][Full Text] [Related]
15. Human synovial fibroblasts produce urokinase-type plasminogen activator.
Medcalf RL; Hamilton JA
Arthritis Rheum; 1986 Nov; 29(11):1397-401. PubMed ID: 3096341
[TBL] [Abstract][Full Text] [Related]
16. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Petruzzelli GJ; Snyderman CH; Johnson JT
Arch Otolaryngol Head Neck Surg; 1994 Sep; 120(9):989-92. PubMed ID: 8074827
[TBL] [Abstract][Full Text] [Related]
17. Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60.
Alving BM; Krishnamurti C; Liu YP; Lucas DL; Wright DG
Thromb Res; 1988 Jul; 51(2):175-85. PubMed ID: 3142093
[TBL] [Abstract][Full Text] [Related]
18. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
[TBL] [Abstract][Full Text] [Related]
19. [The RH-PA cell line--a source for obtaining the urokinase-type plasminogen activator].
Kapina MA; Zelenin MG; Glukhova LA; Egorov BB
Antibiot Khimioter; 1989 Dec; 34(12):893-8. PubMed ID: 2517003
[TBL] [Abstract][Full Text] [Related]
20. Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma.
Ramshaw IA; Badenoch-Jones P; Grant A; Maxted M; Claudianos C
Invasion Metastasis; 1986; 6(3):133-44. PubMed ID: 3733365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
